Published in:
01-07-2021 | Prostate Cancer | Letter to the Editor
Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al.
Authors:
Cem Onal, Ezgi Oymak, Ozan Cem Guler
Published in:
Medical Oncology
|
Issue 7/2021
Login to get access
Excerpt
We read the article by Triggiani et al. [
1] with great interest and commend all authors for evaluating the potential impact of upfront metastasis-directed therapy (MDT) in terms of prolongation of castration-sensitive phase in a series of oligorecurrent castration-sensitive prostate cancer (PC) patients. However, some issues require clarifications. …